Never Run Out Of Buyers To Sell To.

Altimmune is a late clinical-stage biopharmaceutical company developing therapies to improve the lives of people living with serious liver diseases. Our lead program is a differentiated dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, currently in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).#ClinicalResearch #LiverCare #BioResearch
Annual Revenue$10M to $25M
Estimated OwnershipPublicBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.